Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;10(2):e15.
doi: 10.1016/S2213-2600(21)00549-X.

Why the application of IVIG might be beneficial in patients with COVID-19

Detlef Kindgen-Milles  1 , Torsten Feldt  2 , Bjoern Erik Ole Jensen  2 , Thomas Dimski  1 , Timo Brandenburger  3
Affiliations
Comment

Why the application of IVIG might be beneficial in patients with COVID-19

Detlef Kindgen-Milles et al. Lancet Respir Med. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DKM received lecture honoraria from Biotest. All other authors declare no competing interests.

Comment in

Comment on

References

    1. Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:158–166. - PMC - PubMed
    1. Guell E, Martín-Fernandez M, De la Torre M, et al. Impact of lymphocyte and neutrophil counts on mortality risk in severe community-acquired pneumonia with or without septic shock. J Clin Med. 2019;8:754. - PMC - PubMed
    1. Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35:2693–2701. - PubMed
    1. Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365:1201–1211. - PubMed
    1. Welte T, Dellinger RP, Ebelt H, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study) Intensive Care Med. 2018;44:438–448. - PMC - PubMed

Substances

LinkOut - more resources